ZA200505990B - Formulations of glucocorticoids to treat pathologic ocular angiogenesis - Google Patents

Formulations of glucocorticoids to treat pathologic ocular angiogenesis

Info

Publication number
ZA200505990B
ZA200505990B ZA200505990A ZA200505990A ZA200505990B ZA 200505990 B ZA200505990 B ZA 200505990B ZA 200505990 A ZA200505990 A ZA 200505990A ZA 200505990 A ZA200505990 A ZA 200505990A ZA 200505990 B ZA200505990 B ZA 200505990B
Authority
ZA
South Africa
Prior art keywords
glucocorticoids
formulations
ocular angiogenesis
pathologic ocular
treat pathologic
Prior art date
Application number
ZA200505990A
Other languages
English (en)
Inventor
David P Bingaman
Abbot F Clark
Jani Rajni
Stella M Robertson
Original Assignee
Alcon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Inc filed Critical Alcon Inc
Publication of ZA200505990B publication Critical patent/ZA200505990B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA200505990A 2003-02-20 2004-02-05 Formulations of glucocorticoids to treat pathologic ocular angiogenesis ZA200505990B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US44894403P 2003-02-20 2003-02-20

Publications (1)

Publication Number Publication Date
ZA200505990B true ZA200505990B (en) 2006-12-27

Family

ID=32908675

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200505990A ZA200505990B (en) 2003-02-20 2004-02-05 Formulations of glucocorticoids to treat pathologic ocular angiogenesis

Country Status (16)

Country Link
US (2) US20040167109A1 (xx)
EP (1) EP1594511A2 (xx)
JP (2) JP2006518383A (xx)
KR (1) KR20050102653A (xx)
CN (1) CN100431544C (xx)
AR (1) AR043252A1 (xx)
AU (1) AU2004212900A1 (xx)
BR (1) BRPI0407742A (xx)
CA (1) CA2516790A1 (xx)
MX (1) MXPA05008396A (xx)
PL (1) PL378209A1 (xx)
RU (1) RU2005129278A (xx)
TW (1) TW200507858A (xx)
UY (1) UY28203A1 (xx)
WO (1) WO2004073608A2 (xx)
ZA (1) ZA200505990B (xx)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20060095974A (ko) * 2003-09-23 2006-09-05 알콘, 인코퍼레이티드 트리암시놀론 아세토나이드 및 아네코르타브 아세테이트주사용 제제
US7257366B2 (en) * 2003-11-26 2007-08-14 Osmosis Llc System and method for teaching a new language
US9693967B2 (en) 2005-09-07 2017-07-04 Southwest Research Institute Biodegradable microparticle pharmaceutical formulations exhibiting improved released rates
JP2009507845A (ja) * 2005-09-07 2009-02-26 サウスウエスト リサーチ インスティテュート 改良された放出速度を示す生分解性微粒子薬学的処方物
BRPI0620249A2 (pt) * 2005-12-22 2011-11-08 Alcon Res Ltd inibidores de c3-convertase para prevenção e tratamento de degeneração macular correlacionada à idade em pacientes com riscos alternativos do fator h de complemento
US20070173538A1 (en) * 2005-12-23 2007-07-26 Alcon, Inc. PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE
GB0625844D0 (en) * 2006-12-22 2007-02-07 Daniolabs Ltd The treatment of macular degeneration
CA2693888A1 (en) * 2007-07-20 2009-01-29 Alcon, Inc. Pharmaceutical formulation for delivery of receptor tyrosine kinase inhibiting (rtki) compounds to the eye
EP3238781B1 (en) * 2010-05-10 2019-07-31 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for the treatment of fluid accumulation in and/ or under the retina
US20170106047A1 (en) * 2014-06-12 2017-04-20 The Research Foundation For The State University Of New York Methods of using gap junctions as therapeutic targets for the treatment of degenerative disorders of the retina

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4975537A (en) * 1985-10-23 1990-12-04 The Upjohn Company Δ9(11) -angiostatic steroids
US4686214A (en) * 1985-10-30 1987-08-11 Alcon Laboratories, Inc. Anti-inflammatory compounds for ophthalmic use
US4771042A (en) * 1985-11-25 1988-09-13 The Upjohn Company Inhibition of angiogenesis involving the coadministration of steroids with heparin or heparin fragments
US4853224A (en) * 1987-12-22 1989-08-01 Visionex Biodegradable ocular implants
US5371078A (en) * 1988-10-31 1994-12-06 Alcon Laboratories, Inc. Angiostatic steroids and methods and compositions for controlling ocular hypertension
US5164188A (en) * 1989-11-22 1992-11-17 Visionex, Inc. Biodegradable ocular implants
US5378475A (en) * 1991-02-21 1995-01-03 University Of Kentucky Research Foundation Sustained release drug delivery devices
US5770592A (en) * 1991-11-22 1998-06-23 Alcon Laboratories, Inc. Prevention and treatment of ocular neovascularization using angiostatic steroids
AU684115B2 (en) * 1993-12-27 1997-12-04 Mitsubishi Chemical Corporation Ophthalmic suspension containing diflupredonate
US5646136A (en) * 1994-01-04 1997-07-08 Duke University Methods of inhibiting angiogenesis and tumor growth, and treating ophthalmologic conditions with angiostatic and therapeutic steroids
US5516522A (en) * 1994-03-14 1996-05-14 Board Of Supervisors Of Louisiana State University Biodegradable porous device for long-term drug delivery with constant rate release and method of making the same
US5869079A (en) * 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
US5773019A (en) * 1995-09-27 1998-06-30 The University Of Kentucky Research Foundation Implantable controlled release device to deliver drugs directly to an internal portion of the body
US5736152A (en) * 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
US6011023A (en) * 1997-08-27 2000-01-04 Alcon Laboratories, Inc. Angiostatic steroids
AU775149B2 (en) * 1999-10-21 2004-07-22 Alcon Inc. Sub-tenon drug delivery
ATE414494T1 (de) * 1999-10-21 2008-12-15 Alcon Inc Medikamentenzuführeinrichtung
US6416777B1 (en) * 1999-10-21 2002-07-09 Alcon Universal Ltd. Ophthalmic drug delivery device
MXPA05000773A (es) * 2002-08-05 2005-04-19 Alcon Inc Uso de acetato de anecortave para la proteccion de la agudeza visual en pacientes con degeneracion macular relacionada con la edad.

Also Published As

Publication number Publication date
TW200507858A (en) 2005-03-01
AR043252A1 (es) 2005-07-20
AU2004212900A1 (en) 2004-09-02
PL378209A1 (pl) 2006-03-20
WO2004073608A2 (en) 2004-09-02
US20040167109A1 (en) 2004-08-26
RU2005129278A (ru) 2006-01-27
JP2006518383A (ja) 2006-08-10
CN1750829A (zh) 2006-03-22
WO2004073608A3 (en) 2005-03-24
KR20050102653A (ko) 2005-10-26
CN100431544C (zh) 2008-11-12
BRPI0407742A (pt) 2006-02-14
MXPA05008396A (es) 2006-03-30
UY28203A1 (es) 2004-08-31
US20060074061A1 (en) 2006-04-06
CA2516790A1 (en) 2004-09-02
JP2007056041A (ja) 2007-03-08
EP1594511A2 (en) 2005-11-16

Similar Documents

Publication Publication Date Title
IL175844A0 (en) Improved stability of progestogen formulations
IL175535A0 (en) Compositions for treatment of neurodegenerative diseases
IL173351A0 (en) Therapy of ocular disorders
HUP0100121A3 (en) Pharmaceutical compositions for the treatment of conditions responsive to testosterone elevation
EP1663222A4 (en) METHODS RELATING TO THE TREATMENT OF GIANCES
IL151517A0 (en) Therapeutic uses of ppar mediators
PL1615622T3 (pl) Preparaty doksycyklin do jednorazowego dziennego podawania
GB2406521B (en) Treatment of hollow anatomical structures
EP1799258A4 (en) METHODS FOR TREATMENT OF ANGIOGENESIS
HUP0300347A3 (en) Improved treatment of neovascularization
ZA200505990B (en) Formulations of glucocorticoids to treat pathologic ocular angiogenesis
GB0305150D0 (en) Use of therapeutic compounds
PL378210A1 (pl) Zastosowanie steroidów do leczenia osób cierpiących z powodu zaburzeń gałki ocznej
EP1896035A4 (en) CARBAZOLE FORMULATIONS FOR THE TREATMENT OF PSORIASIS AND ANGIOGENESIS
EP1740541A4 (en) THERAPEUTIC FORMULATIONS OF DESOXYEPOTHILONES
MXPA03007653A (es) Uso de lp82 para tratar trastornos hematopoyeticos.
TW577324U (en) Improved structure of auxiliary walker
EP1404308A4 (en) TREATMENT OF SECONDARY DISORDERS CAUSED BY ORGANIC DEFICIENCIES
EP1660685A4 (en) ANTISENSE INHIBITION OF LAMINININ-8 EXPRESSION FOR THE INHIBITION OF HUMAN GLIOMES
EP1667543A4 (en) CONVERTIBLE BATHROOM SUBSIDY OR TRANSFORMABLE SWIMMING TROUSERS
EP1613268A4 (en) PROCESS FOR INHIBITING THE ANGIOGENESIS
PT1656358E (pt) Polimorfo est?vel de mesilato de bifeprunox
AU4838301A (en) Treatment of disorders relating to the serotonergic system
GB0306782D0 (en) Treatment of infection due to clostridium difficile
GB0329929D0 (en) Improvements to decontamination of seeds